The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone marrow in 1976, have been identified in nearly all tissues of human body now. The multipotency of MSCs allows them to give rise to osteocytes, chondrocytes, adipocytes, and other lineages. Moreover, armed with the immunomodulation capacity and tumor-homing property, MSCs are of special relevance for cell-based therapies in the treatment of cancer. However, hampered by lack of knowledge about the controversial roles that MSC plays in the crosstalk with tumors, limited progress has been made with regard to translational medicine. Therefore, in this review, we discuss the prospects of MSC-associated anticancer strategies in light of therapeutic mechanisms and signal transduction pathways. In addition, the clinical trials designed to appraise the efficacy and safety of MSC-based anticancer therapies will be assessed according to published data.

中文翻译：

---

间充质干细胞/基质细胞在癌症治疗中的应用

多能间充质干细胞/基质细胞（MSCs）最初于1976年从骨髓中发现，现在已在人体几乎所有组织中被发现。间充质干细胞的多能性使其能够产生骨细胞、软骨细胞、脂肪细胞和其他谱系。此外，间充质干细胞具有免疫调节能力和肿瘤归巢特性，对于癌症治疗中的细胞疗法具有特殊意义。然而，由于缺乏对 MSC 在与肿瘤串扰中所扮演的有争议的作用的了解，转化医学方面取得的进展有限。因此，在这篇综述中，我们从治疗机制和信号转导途径的角度讨论了间充质干细胞相关抗癌策略的前景。此外，旨在评估基于间充质干细胞的抗癌疗法的有效性和安全性的临床试验将根据已发表的数据进行评估。